The results were released to the media at a press conference before most doctors or trial participants could read the actual paper, and hormone therapy use collapsed almost immediately afterward: prescriptions fell 66 percent for one major combined product and 33 percent for an estrogen-only product within a year, and national survey data show oral hormone use among women 40 and older fell from over 22 percent in 1999-2000 to under 5 percent by 2009-2010, a sustained, not temporary, drop.
One widely cited modeling study estimated tens of thousands of excess deaths among hysterectomized women aged 50-59 who avoided estrogen therapy during the decade after 2002, a group for whom the trial's own data had shown a mortality benefit; the assumptions behind that estimate are debated, but it has been peer-reviewed and widely cited.
There is little dispute that the announcement itself, and the collapse in hormone use that followed, happened roughly as described; the genuine disagreement is over how much of the collapse represented an appropriate response to real trial findings versus a costly overcorrection, and how reliable the excess-death modeling estimate is.
What the research shows, and which source each finding rests on
WHI results were released to the media at a July 2002 press conference ahead of the journal publication date, before most prescribing clinicians or trial participants could read the paper.
US hormone therapy prescriptions fell 66 percent for one major combined product and 33 percent for an estrogen-only product within a year of the 2002 announcement, projecting back to 57 million prescriptions for 2003 after rising from 58 million (1995) to 90 million per year (1999-2002).
National survey data show oral postmenopausal hormone use among US women 40 and older fell from 22.4 percent in 1999-2000 to 4.7 percent in 2009-2010, a sustained decline, not a temporary blip.
One modeling study estimated that among hysterectomized women aged 50-59, the group for whom WHI's own data showed a mortality benefit with estrogen alone, avoidance of estrogen therapy was associated with a minimum of 18,601 and as many as 91,610 excess premature deaths over the decade 2002-2011.
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
the collapse was a costly, largely avoidable overcorrection
Robert Langer (a WHI clinical center principal investigator), Mary Claire Haver, and other corpus clinicians
Langer, who helped run the trial, describes the alarming initial report and a worldwide collapse in hormone use driven by fear of breast cancer, arguing the facts most women and clinicians use to decide about hormone therapy are frequently wrong or misapplied; Haver separately describes her own residency training in menopause care effectively stopping for about 20 years after the announcement.
the modeling estimate of excess deaths is a real but contested number, not a settled fact
a cautious reading of the mortality-modeling literature
The excess-death estimate is peer-reviewed and widely cited, but it is a modeling study built on specific assumptions about which women would have benefited and how consistently they would have used therapy, and those assumptions are debated even by researchers sympathetic to the underlying argument.
What would settle it: This is now largely a matter of documented history for the announcement and prescribing-collapse facts; the excess-death magnitude specifically would be refined by further mortality modeling using updated assumptions and longer follow-up data.
What is really going on here
- How does my personal risk profile compare with the group that the excess-mortality estimate is describing?
- If I'm avoiding hormones out of fear from that era, is that fear based on data that applies to my situation?
Questions for your doctor
- Given how menopause care training changed after 2002, how current is the guidance I'm receiving?
- What are the risks of NOT taking hormone therapy in my specific situation, not just the risks of taking it?
- How would you summarize what changed in the evidence since 2002?
Questions with no answer yet
How reliable is the estimate of tens of thousands of excess deaths from estrogen avoidance, given that it rests on specific modeling assumptions rather than directly observed outcomes?
Partly studiedWhat is known: The estimate is peer-reviewed and widely cited, but it is a modeling study built on assumptions about which women would have benefited and how consistently they would have used therapy, and those assumptions are debated even by researchers sympathetic to the underlying argument.
What would test it: Updated mortality modeling using more recent data and a wider range of assumption sets, or, where possible, direct comparison against observed mortality trends in the affected population.
Would a similarly abrupt, large-scale collapse in use happen again today if a comparably alarming finding were announced the same way?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: No comparable event has occurred since 2002 to test whether prescribing behavior and public reaction would follow the same pattern under today's media environment and menopause-education landscape.
What would test it: This is not a question research can currently answer directly; it would require observing how the field responds to a future major safety signal, if one occurs.
Sources
- 1.The evidence base for HRT: what can we believe?Langer RD, Climacteric 2017 · Review, opinion or mechanism
- 2.National use of postmenopausal hormone therapy: annual trends and response to recent evidence.Hersh AL, Stefanick ML, Stafford RS, JAMA 2004 · Comparative or small study
- 3.A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010.Sprague BL, Trentham-Dietz A, Cronin KA, Obstet Gynecol 2012 · Comparative or small study
- 4.The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years.Sarrel PM et al., Am J Public Health 2013 · Randomised trial
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- Does hormone therapy cause breast cancer?
- What does it actually mean that hormone therapy increases breast cancer risk by 26 percent?
- Was the WHI hormone therapy trial stopped because women were dying of breast cancer?
- Is estrogen-only hormone therapy safer for breast cancer risk than combined estrogen-progestin therapy?
- Is bioidentical or micronized progesterone safer for breast cancer risk than the older synthetic progestins?
- Can breast cancer survivors take hormone therapy for their menopause symptoms?
- Back to topic: Hormone therapy and breast cancer